%0 Journal Article
%A Gutierrez, Antonio
%A Bento, Leyre
%A Diaz-Lopez, Antonio
%A Barranco, Gilberto
%A Garcia-Recio, Marta
%A Lopez-Guillermo, Armando
%A Dlouhy, Ivan
%A Rovira, Jordina
%A Rodriguez, Mario
%A Sanchez Pina, Jose María
%A Baile, Monica
%A Martín, Alejandro
%A Novelli, Silvana
%A Sancho, Juan-Manuel
%A García, Olga
%A Salar, Antonio
%A Bastos-Oreiro, Mariana
%A Rodriguez-Salazar, Mª José
%A Fernandez, Ruben
%A de la Cruz, Fatima
%A Queizan, Jose Antonio
%A González de Villambrosia, Sonia
%A Cordoba, Raul
%A López, Andres
%A Luzardo, Hugo
%A García, Daniel
%A Sastre-Serra, Jordi
%A Garcia, Juan Fernando
%A Montalban, Carlos
%A Cabanillas, Fernando
%A Rodríguez, Jose
%T Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
%D 2020
%U http://hdl.handle.net/10668/14791
%X Diffuse large B-cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%-40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot identify a very high-risk (HR) subset. The MD Anderson Cancer Center reported a score in the prerituximab era exclusively considering tumor-related variables: Tumor Score (TS). We aim to validate TS in the rituximab era and to analyze its current potential role. From GELTAMO DLBCL registry, we selected those patients homogeneously treated with R-CHOP (n = 1327). Five-years PFS and OS were 62% and 74%. All variables retained an independent prognostic role in the revised TS (R-TS), identifying four different risk groups, with 5-years PFS of 86%, 71%, 50%, and very HR (28%). With a further categorization of three variables of the original TS (Ann Arbor Stage, LDH and B2M), we generated a new index that allowed an improvement in HR assessment. (a) All variables of the original TS retain an independent prognostic role, and R-TS remains predictive in the rituximab era; (b) R-TS and additional categorization of LDH, B2M, and AA stage (enhanced TS) increased the ability to identify HR subsets.
%K diffuse large B-cell lymphoma
%K international prognostic index
%K prognosis
%K score
%K tumor score
%~